Camlin Fine Sciences Ltd Q3 FY2025 Concall Summary

Key Takeaways

• Stabilizing quarter with a pricing tailwind: Turnover rose 2% and operational EBITDA margin improved from 10% to 12%, while the US anti-dumping duty on Chinese vanillin is already lifting prices almost daily.
• Vanillin is the swing factor: Utilization is climbing toward 70%, pricing is expected to improve 10–15%, and the combined Catechol-plus-Vanillin operation should break even at 75% utilization in FY26.
• Blends is the quiet compounder: The vertical has been growing at 20% for several years, with enough market visibility to sustain 15–20% for at least the next few years.
• Europe remains a drag, but the exit is in sight: Losses continue because Italian law requires the plant to stay staffed while hazardous intermediates are evacuated; fixed costs should reduce considerably from Q1 FY26.
• What to watch next quarter: Whether the final anti-dumping orders in Europe (June) and the US lock in the pricing improvement, and whether the European cost reduction actually materializes in Q1.

Vanillin: The Pricing Inflection

• Anti-dumping catalyst: The US imposed a preliminary anti-dumping duty of 187% on Chinese vanillin in mid-January, and prices have been improving since December when the duty was first expected.
• Pricing trajectory: Sale prices are improving almost daily; Q4 pricing is already better than Q3, and management expects the overall vanillin business to see at least a 10–15% pricing improvement.
• Volume ramp in parallel: Output has increased from roughly 500 to 600 metric tons, with Dahej slowly ramping toward 70% utilization by year-end and 75% targeted for FY26.
• Contracting strategy is deliberately open: No long-term or early contracts have been signed for FY26 because pricing is dynamic and anti-dumping outcomes are uncertain; existing contracts run out in Q4, leaving hardly any contracted quantities for Q1 FY26.
• The China wildcard: If China were to dump again, the US ADD plus potential new tariffs would likely floor prices at not less than \$14–\$15, a level that still represents improvement.
• Cost leverage still to come: At 100% utilization, vanillin cost from the current \$8.50–\$9.00 should come down by about 10%, but 100% is not targeted until FY27.

Momaya: "The price increase would typically be in the US would be about 20% or so higher than it was in the last quarter. And of course, everybody now wants to look at longer-term contracts because there could be some shortages in the market."

Blends: The Reliable Growth Engine

• 20% growth, durable trajectory: The blends vertical has been growing at 20% for three to five years, with enough market visibility to sustain 15–20% for at least the next few years.
• Geographic breadth: Extremely good performance in the American continent and improving in India; 20% growth expected across all geographies for FY26.
• Moat is technical service: The business requires technical service and deep understanding of ingredient functions, creating a barrier that supports sustained growth.
• End-market diversification: Focus areas span human food, animal feed (poultry, dairy, swine, aqua feed), and pet food (dog, cat), spreading demand risk across multiple protein and companion-animal cycles.

Europe Wind-Down: The Known Drag

• Why losses persist: Italian law requires employees to be maintained while intermediate materials are evacuated; the process is slow because hazardous chemicals demand factory security, utilities, and clearance from local authorities.
• The timeline: Materials evacuation should complete in Q1 FY26, after which costs can be rationalized; by Q2 FY26, the loss will become much smaller.
• Asset already impaired: The factory was impaired last quarter and may be kept mothballed rather than sold.
• Fixed cost reduction: Management expects European fixed costs to reduce considerably from Q1 FY26 once intermediate materials in tanks are evacuated.

Catechol & Hydroquinone: The Combined Operation

• No standalone disclosure: Management declined to break out the Catechol loss separately, calling it a joint product with hydroquinone; if vanillin is being produced, catechol is not sold in the market.
• The chain-level math: The hydroquinone chain makes enough profit to justify carrying catechol, so the combined operation is assessed as a whole.
• Breakeven threshold: At roughly 70% vanillin utilization, the combined catechol-plus-vanillin operation should break even; management expects this by FY26 assuming 75% utilization.
• Catechol plant standalone: Currently breaking even on its own.

Parab: "If I stop at that level, the hydroquinone chain is making enough profit to justify the carrying of Catechol."

Vitafor & Product Expansion

• Integration complete: The Vitafor acquisition is fully integrated; applications for registrations in several countries have been made, with some starting to come through.
• Current profitability: Break-even at the EBITDA level, but not yet at the bottom line.
• Growth target: Management aims to grow Vitafor by at least 20–25% in FY26, and thereafter keep growing at least 20% a year.
• Product rollouts underway: Launches starting in Mexico, Colombia, Peru, and India, with the US and Brazil also to be launched.
• Vanillin basket completion: The company produces vanillin and ethyl vanillin and plans to enter natural vanillin over time to complete the portfolio.

Balance Sheet & Capital Allocation

• Rights issue completed: Monies received last week with an overwhelming response; funds are kept in reserve for debt repayment but will not be used to accelerate the schedule.
• NCD repaid: An NCD taken in December for liquidity easing was repaid along with interest.
• Debt repayment plan: Regular repayment of ₹45–50 crores per annum.
• Interest cost pressure: Borrowed ₹100 cr in long-term foreign-currency debt; dollar appreciation against local currencies is weighing on the balance sheet, though the impact is largely unrealized and would reverse on any rupee or local-currency appreciation.
• Forex volatility hit P&L: Other income from a prior-quarter forex gain was not repeated; foreign currency volatility resulted in a loss this quarter.
• FY26 CAPEX: ₹30–35 crores, largely maintenance.

Guidance & Commitments

Key Metrics